Fontanet Bijou

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Carole Soussain, Sylvain Choquet, Marie Blonski et al. · European Journal of Cancer · 2019 · 318 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group

Emmanuelle Tchernonog, P. Faurie, Paul Coppo et al. · Annals of Oncology · 2016 · 131 citations

Medicine, Hematology, Oncology +15

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Cédric Rossi, Julia Gilhodes, Marie Maerevoet et al. · American Journal of Hematology · 2018 · 122 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone

Anna L. Godfrey, Edwin Chen, Francesca Pagano et al. · Blood · 2012 · 105 citations · Full text

Life Sciences, Genetics, Molecular Genetics +6

ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Pier Luigi Zinzani, Christopher R. Flowers, Fontanet Bijou et al. · Journal of Clinical Oncology · 2023 · 98 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +11